Why CAMP4?
Leadership
Investors
About Our Name
RAP Platform
RNA Actuators
Programmable Therapeutics
Publications & Presentations
Pipeline
Newsroom
Join the Adventure
Recent News
September 17, 2024
CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders
Read More
Contact Us
Privacy Policy
Menu
Newsroom
Views and missives from the frontier
All
Press Releases
Perspectives
In the News
Videos
September 17, 2024
Press Releases
CAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders
August 27, 2024
Press Releases
CAMP4 Therapeutics Secures Rare Pediatric Disease Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders
March 21, 2024
Press Releases
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
September 5, 2023
Press Releases
CAMP4 Therapeutics to Present at Upcoming Industry and Investor Conferences
July 5, 2023
Press Releases
Research from the Lab of CAMP4 Co-Founder Richard Young Shows That RNA Binding to Transcription Factors Fine-Tunes Gene Expression
July 20, 2022
Press Releases
CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic
April 19, 2022
Press Releases
CAMP4 Therapeutics Promotes Kelly Gold to Chief Financial Officer
March 14, 2022
Press Releases
CAMP4 Therapeutics Appoints Veteran Drug Developer Ann Barbier, M.D., Ph.D. as Chief Medical Officer
1
2
3
»
Media Contact:
PR@camp4tx.com
Top
